Statins and cancer [5]

Epidemiology

Volumn 18, Issue 4, 2007, Pages 520-521

  Coogan, Patricia ^a   Rosenberg, Lynn ^a   Strom, Brian ^b  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BLADDER CANCER; BREAST CANCER; CANCER RISK; COLORECTAL CANCER; ENDOMETRIUM CANCER; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; KIDNEY CANCER; LETTER; LEUKEMIA; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; RISK REDUCTION;

EID: 34250743248     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3180646718     Document Type: Letter

References (7)

1. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer [letter]. Epidemiology. 2007;18:520.
2. Coogan PF, Rosenberg L, Strom BL. Statin use and risk of 10 cancers. Epidemiology. 2007;18:213-219.
3. Riley TN, DeRuiter J. How does rosuvastatin calcium (Crestor) differ from other HMG-CoA inhibitors? US Pharm. 2004;29:1-5.
4. Corsini A, Bellosta F, Baetta R, et al. New insights in the pharmacodynamic and pharma-cokinetic properties of statins. Pharmacol Ther. 1999;84:414-418.
5. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
6. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006;98:700-707.
7. Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(Suppl III):50-57.